Related references
Note: Only part of the references are listed.Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses
Gregg J. Silverman et al.
JOURNAL OF RHEUMATOLOGY (2014)
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis
Maria Greenwald et al.
ARTHRITIS RESEARCH & THERAPY (2014)
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
M. C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2013)
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
William Stohl et al.
JOURNAL OF RHEUMATOLOGY (2013)
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Results of a Phase II, Randomized, Placebo-Controlled Trial
R. F. van Vollenhoven et al.
ARTHRITIS AND RHEUMATISM (2011)
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial
M. C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2011)
Share Paper
